Diffuse Cutaneous Systemic Sclerosis (dcSSc) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Takeda, Seagen, Kadmon Pharma

Diffuse Cutaneous Systemic Sclerosis (dcSSc) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Takeda, Seagen, Kadmon Pharma
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Diffuse Cutaneous Systemic Sclerosis (dcSSc) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Diffuse Cutaneous Systemic Sclerosis (dcSSc) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Diffuse Cutaneous Systemic Sclerosis Market. 

The Diffuse Cutaneous Systemic Sclerosis Pipeline report embraces in-depth commercial, regulatory, and Diffuse Cutaneous Systemic Sclerosis clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Diffuse Cutaneous Systemic Sclerosis drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Diffuse Cutaneous Systemic Sclerosis (dcSSc) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Diffuse Cutaneous Systemic Sclerosis treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Diffuse Cutaneous Systemic Sclerosis therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Diffuse Cutaneous Systemic Sclerosis companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Diffuse Cutaneous Systemic Sclerosis drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Diffuse Cutaneous Systemic Sclerosis therapeutic market.

Diffuse Cutaneous Systemic Sclerosis (dcSSc) Therapeutics Landscape

Although several treatment options are available, there is no curing treatment to date. Present therapies postpone disease deterioration but do not prevent serious disease complications. Therapeutic options for DcSSc according to the EULAR treatment recommendations 2016 are methotrexate, cyclophosphamide, or mycophenolate mofetil and in selected patients autologous stem cell transplantation. It is important to consider other (composite) outcome measurements for future research, which perhaps measure the effectiveness of therapy more adequately.

Tumor Necrosis Factor (TNF) Inhibitors are drugs that help stop inflammation and are used to treat Diffusion cutaneous systemic sclerosis. Infliximab, adalimumab, etanercept, and rituximab are used by themselves or in combination with other medications such as prednisone, methotrexate, hydroxychloroquine, leflunomide or sulfasalazine.

There are approx. 15+ key companies developing therapies for Diffuse Cutaneous Systemic Sclerosis. Some of the leading players developing therapies in the market include Kadmon Corporation, Emerald Health Pharmaceuticals, Mitsubishi Tanabe Pharma, Horizon Therapeutics, Galapagos NV, and others. Currently, Kadmon Pharmaceuticals is leading the therapeutics market with its Diffuse Cutaneous Systemic Sclerosis drug candidates in the most advanced stage of clinical development.

Diffuse Cutaneous Systemic Sclerosis (dcSSc) Companies Actively Working in the Therapeutic Market Include:

  • Kadmon Pharmaceuticals

  • Talaris Therapeutics

  • Horizon Therapeutics

  • Mitsubishi Tanabe Pharma

  • Takeda Oncology

  • Seagen

And Many Others

Emerging and Marketed Diffuse Cutaneous Systemic Sclerosis (dcSSc) Drugs Covered in the Report Include:

  • FCR 001: Talaris Therapeutics

  • Belumosudil: Kadmon Pharmaceuticals

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Diffuse Cutaneous Systemic Sclerosis Companies Working in the Market @


Analysis of Emerging Diffuse Cutaneous Systemic Sclerosis (dcSSc) Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Diffuse Cutaneous Systemic Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide

  • Peptide

  • Small molecule

Learn How the Diffuse Cutaneous Systemic Sclerosis Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Diffuse Cutaneous Systemic Sclerosis Treatment Patterns

4. Diffuse Cutaneous Systemic Sclerosis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Diffuse Cutaneous Systemic Sclerosis Late Stage Products (Phase-III)

7. Diffuse Cutaneous Systemic Sclerosis Mid-Stage Products (Phase-II)

8. Diffuse Cutaneous Systemic Sclerosis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Diffuse Cutaneous Systemic Sclerosis Discontinued Products

13. Diffuse Cutaneous Systemic Sclerosis Product Profiles

14. Major Diffuse Cutaneous Systemic Sclerosis Companies in the Market

15. Key Products in the Diffuse Cutaneous Systemic Sclerosis Therapeutics Segment

16. Dormant and Discontinued Products

17. Diffuse Cutaneous Systemic Sclerosis Unmet Needs

18. Diffuse Cutaneous Systemic Sclerosis Future Perspectives

19. Diffuse Cutaneous Systemic Sclerosis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @




About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

“Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Chronic Inflammatory Demyelinating Polyneuropathy market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology